By Artem Andrianov, Ph.D., MBA|2017-06-14T09:32:41+02:00June 14, 2017|Comments Off on ICH GCP Goes Risk-based
About the Author: Artem Andrianov, Ph.D., MBA
Professional in the integration of data-driven Risk-based Quality Management (RBQM) process in international clinical trials of pharmacology.
Speaker at regional and global conferences such as: DIA, Health 2.0, DGGF, etc.
18+ years of experience in data quality projects and biostatistics for the pharmaceutical industry.
Life passion: improving clinical research with RbM, driving the RBQM research to new frontiers for CROs, pharma and biotech companies.